Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
about
Specific in vivo knockdown of protein function by intrabodiesA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic miceNovel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody librariesIntranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 miceRestricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide.Structure-based design of conformation- and sequence-specific antibodies against amyloid β.Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's diseaseAssessment of antibody library diversity through next generation sequencing and technical error compensation.Immunosympathectomy as the first phenotypic knockout with antibodies.Molecular Mechanism and Energy Basis of Conformational Diversity of Antibody SPE7 Revealed by Molecular Dynamics Simulation and Principal Component AnalysisDeveloping intrabodies for the therapeutic suppression of neurodegenerative pathology.Basic mechanisms of neurodegeneration: a critical update.Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Progress in the development of therapeutic antibodies targeting prion proteins and beta-amyloid peptides.Antibody-based therapy in Alzheimer's disease.Intranasal delivery of therapeutic proteins for neurological diseases.Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.Post-translational selective intracellular silencing of acetylated proteins with de novo selected intrabodies.Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum.The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.NGF steers microglia toward a neuroprotective phenotype.
P2860
Q26801077-C539C0CA-8CCE-40D7-A4E2-29564D907980Q27010785-FA0B0A2C-62A7-472A-A112-1C1A89AB7A94Q30541267-5C847B7D-C3C0-49A8-94DC-CF34BE98253FQ33572338-E05DC414-AC0F-45EE-87FE-3534FB1FE388Q34292513-AC9D273C-488F-4274-8A56-C5688D2A151EQ34574825-DA3E99ED-31CB-428A-AB9E-04B47B8359C8Q35657526-0FE465C1-2D31-4CE1-A038-D74CA64F872CQ36012349-5638B12A-FF2D-43CB-B610-65C32B680B81Q36142379-D51E1FD3-273B-4D8B-99C2-F3FB53EABB4BQ36372120-9C1B5918-BAF0-4497-9068-B46CEE537EC6Q36729840-C7A4ACBC-53CB-4FDD-AACE-DC41D828DF51Q37405719-69676A8C-F951-4DA0-8523-B484FE24F98FQ37571975-ED1DCAB8-D18F-4050-A547-AB127004F3ECQ37673274-F959C2E7-669A-40E6-B8DB-FC68F8392D16Q37688886-BDF679C4-31AA-4415-AAC8-533673B97BFCQ37785871-8B05F671-2E07-4E10-80F6-EEF6782FC197Q37831912-6C190DD7-414C-45BA-AE02-8D5E4545B3E6Q37880893-8094B58B-5CAF-4A98-AF8E-C76B13CE366AQ38240609-0A4D42B3-9B85-43BA-80CE-EA71A92BF137Q38881198-E9884C94-AC46-411E-A84B-97BA42E1EBE4Q39864280-020D67C8-A381-4DC0-BB4F-C12645EC8EA1Q40378909-29A14BAD-F0E6-45A6-ADE8-27BFD6D6C5A5Q40470312-1842A464-0EE9-4FC6-B291-717F349A7B01Q46310832-3F6112B1-8267-45F5-A22D-BB0EEE1A8B4EQ46341580-BED97AB1-A3D4-4F6A-8798-C81F76E2C959Q55250655-8667D4CA-A8FA-4E2A-8673-5E69FEB38F89
P2860
Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@ast
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@en
type
label
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@ast
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@en
prefLabel
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@ast
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@en
P1476
Direct in vivo intracellular s ...... imer's amyloid-beta oligomers.
@en
P2093
Isabella Cannistraci
Michela Visintin
P304
P356
10.1016/J.JMB.2009.01.061
P407
P577
2009-02-04T00:00:00Z